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Background: High-dose tissue-specific delivery of therapeutic agents would be a valuable 
clinical strategy. We have previously shown that repeated transcranial focused ultrasound is 
able to increase the delivery of Evans blue significantly into brain tissue. The present study 
shows that repeated pulsed high-intensity focused ultrasound (HIFU) can be used to deliver 
high-dose atherosclerotic plaque-specific peptide-1 (AP-1)-conjugated liposomes selectively 
to brain tumors.
Methods: Firefly luciferase (Fluc)-labeled human GBM8401 glioma cells were implanted 
into NOD-scid mice. AP-1-conjugated liposomal doxorubicin or liposomal doxorubicin alone 
was administered followed by pulsed HIFU and the doxorubicin concentration in the treated 
brains quantified by fluorometer. Growth of the labeled glioma cells was monitored through 
noninvasive bioluminescence imaging and finally the brain tissue was histologically examined 
after sacrifice.
Results: Compared with the control group, the animals treated with 5 mg/kg injections of 
AP-1 liposomal doxorubicin or untargeted liposomal doxorubicin followed by repeated pulsed 
HIFU not only showed significantly enhanced accumulation of drug at the sonicated tumor 
site but also a significantly elevated tumor-to-normal brain drug ratio (P , 0.001). Combining 
repeated pulsed HIFU with AP-1 liposomal doxorubicin or untargeted liposomal doxorubicin 
has similar antitumor effects.
Conclusion: This study demonstrates that targeted or untargeted liposomal doxorubicin, 
  followed by repeated pulsed HIFU, is a promising high-dose chemotherapy method that allows 
the desired brain tumor region to be targeted specifically.
Keywords: repeated focused ultrasound, interleukin-4 receptor, blood-brain barrier, brain 
tumor, target drug delivery
Introduction
Malignant glioma remains one of the most deadly types of tumor in humans, and 
glioblastoma multiforme is one of the most common forms of glioma. It is difficult 
to treat gliomas completely by surgical resection, and therefore radiotherapy and 
chemotherapy are used to remove residual microscopic tumor material.1 Radio-
therapy can induce developmental delays, so chemotherapy is recommended as 
the first line of treatment for children. Presently, chemotherapies are ineffective 
because many drugs do not reach therapeutic levels in the tumor tissue, either 
due to limited lipid solubility or to an inability to penetrate an intact blood-brain 
barrier.2 Over the last decade, high-dose chemotherapy has been extensively inves-
tigated as first-line therapy in patients having brain tumors with a poor prognosis. 
Previous studies have demonstrated that first-line, high-dose chemotherapy may 
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have a potential survival benefit compared with historical 
controls treated with standard-dose therapy.3,4
It has been reported that human brain tumor cell lines 
express high levels of plasma membrane interleukin-4 
receptors.5 Moreover, human brain tumors in situ overex-
press interleukin-4 receptors compared with normal brain 
tissue.6 In an immunodeficient xenograft model of human 
glioblastoma multiforme, an interleukin-4 receptor-targeted 
cytotoxin has been shown to have a remarkable antitumor 
effect.7 These findings show that therapeutic agents that 
bind to interleukin-4 receptors may be a useful approach to 
tumor treatment.8 Our previous work has demonstrated that 
the concentration of Evans blue in tumors and the tumor-
to-normal brain ratio of Evans blue in the brain is elevated 
after blood-brain barrier disruption induced by pulsed-high 
intensity focused ultrasound (HIFU) in the presence of 
microbubbles. In these circumstances, repeated pulsed HIFU 
exposure is able to increase further the efficiency of Evans 
blue delivery into the brain.9–12 Another study has shown 
that magnetic resonance imaging (MRI)-guided focused 
ultrasound is able to achieve therapeutic levels of liposomal 
doxorubicin in the brain.13 It has been pointed out in other 
studies that doxorubicin has potential when used clinically 
against both primary and metastatic brain tumors and that 
there is improved survival of glioma patients treated by direct 
intratumoral infusion of doxorubicin; furthermore, doxoru-
bicin is useful against multiple tumor types.14,15 However, 
the concentration of chemotherapeutics required to achieve 
clinically effective cytotoxicity in tumors is limited by tissue 
toxicity and by the physiological barriers that prevent the 
delivery of drugs to the tumor.16
Glioblastoma multiforme can be highly vascularized 
with a leaky vasculature, and thus may be amenable to 
liposome-based drug delivery systems that lead to enhanced 
drug deposition while limiting systemic drug exposure.17 
Receptor-targeted liposomal doxorubicin has been found 
to be effective in targeting glioma tumors in a brain tumor 
model.18,19 Here, we designed a ligand from atherosclerotic 
plaque-specific peptide-1 (AP-1) selected from phage display 
libraries and can locate atherosclerotic plaque tissue and bind 
to the interleukin-4 receptor because it has the same bind-
ing motif to the interleukin-4 protein.8 Specifically, in order 
to allow more specific and efficient delivery of liposomal 
doxorubicin to brain tumors, an AP-1 actively targeted 
liposomal antitumor drug specific for interleukin-4 receptors, 
which is present on the cell membrane of malignant tumors, 
has been developed. Previous work has demonstrated that 
AP-1-labeled nanoparticles can be used for targeted drug 
delivery to tumor tissue.20,21 In this study, the integration of 
AP-1 liposomal doxorubicin and repeated pulsed HIFU was 
used to deliver and concentrate this high-dose chemothera-
peutic agent in brain tumors by the usual systemic dosage. 
Our aim was to investigate the efficacy of this combined 
technology using an intracranial brain tumor model.
Materials and methods
Preparation of AP-1-labeled liposomal 
doxorubicin
Liposomal doxorubicin was prepared using a solvent 
injection method plus remote loading procedure. Briefly, 
hydrogenated soybean L-α-phosphatidylcholine (95.8 mg, 
Avanti Polar Lipids Inc, Alabaster, AL), cholesterol (31.9 mg, 
Sigma-Aldrich, St Louis, MO) and 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000] (DSPE-PEG 2000, 31.9 mg, Avanti Polar Lipids) 
were dissolved and well mixed in 1 mL absolute ethanol at 
60°C. The lipid containing ethanol was then injected into a 
9 mL solution of 250 mM ammonium sulfate and stirred 
for one hour at 60°C. The mixture was then extruded five 
times through polycarbonate membranes, each of different 
pore size (Isopore Membrane Filter, Millipore, Billerica, 
MA; 0.4, 0.2, 0.1, and 0.05 µm) consecutively in that order 
at 60°C using high-pressure extrusion equipment (Lipex 
Biomembranes, Vancouver, BC); this produced smaller and 
smaller sized liposomes.
The liposome suspension was then dialyzed five times 
against large amounts of 10% sucrose containing 5 mM 
NaCl to remove free ammonium sulfate and ethanol. After 
dialysis, the liposome suspension was placed in a 50 mL glass 
bottle in 60°C water bath and was mixed with doxorubicin 
in a drug to lipid ratio of 1/9 (w/w), with a final doxorubicin 
concentration of 2 mg/mL in a 10% sucrose solution. The 
bottle was intermittently shaken in the water bath for one 
hour at 60°C and then cooled down to 4°C immediately. The 
final product was the liposomal doxorubicin.
Due to the presence of a thiol group on each cysteine of 
the AP-1 peptide (CRKRLDRNC), it is possible to couple 
AP-1 to liposomes by the thiol-maleimide reaction. Briefly, 
AP-1 peptide was conjugated to 1,2-distearoyl-sn-glycero-
3-  phosphoethanolamine-N-[maleimide(polyethylene 
glycol)-2000] (DSPE-PEG2000-MAL, Avanti Polar 
  Lipids) by adding AP-1 to a DSPE-PEG2000-MAL 
micelle solution at a 2:1 molar ratio, while still mixing at 
4°C overnight. The free thiol groups were measured with 
5,5′-  dithiobis-(2-nitrobenzoic acid, Ellman’s reagent, 
  Sigma-Aldrich) at an ultraviolet wavelength of 420 nm, 
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which confirmed that most of the AP-1 was conjugated with 
the DSPE-PEG2000-MAL. The AP-1-conjugated DSPE-
PEG2000 was transferred into the preformed liposomal doxo-
rubicin at a 1.5% molar ratio of total lipid components and 
incubated at 60°C for one hour to obtain the AP-1 liposomal 
doxorubicin (Figure 1A). The composition and properties of 
each preparation are given in Table 1.
Intracranial glioma xenograft model
Male 6–8-week-old NOD-scid mice were anesthetized by 
intraperitoneal administration of pentobarbital at a dose 
of 40 mg/kg bodyweight. All procedures were performed 
according to ethical guidelines approved by our Animal Care 
and Use Committee. The mice were shaved on the head above 
the nape of the neck, scrubbed with betadine/alcohol, and 
immobilized in a Cunningham mouse/neonatal rat adaptor 
stereotactic apparatus (Stoelting, Wood Dale, IL). A 5 mm 
skin incision was made along the sagittal suture line and a 
burr hole drilled into the skull. Malignant human brain glioma 
cells (GBM8401) were transformed with the luciferase gene 
(GBM8401-luc), and 2 × 105 GBM8401-luc cells in 2 µL 
culture medium were then injected into the brains of the 
mice. The glioma cells were stereotactically injected into a 
single location in the left hemisphere (0.14 mm anterior and 
2.0 mm lateral to the bregma) of each mouse at a depth of 
3.5 mm from the brain surface. Next, the burr holes in the 
skull were sealed with bone wax and the wound was flushed 
with iodinated alcohol. Bioluminescence quantification of 
the tumor cells and the established tumor was determined 
by bioluminescence imaging.
Flow cytometric analysis
For detection of cell surface interleukin-4 receptor   expression 
on GBM8401-luc cells, the cells were fixed by 1.5% para-
formaldehyde and then stained with anti-interleukin-4 
receptor monoclonal antibody (Sf 21-derived rhIL-4R; R&D 
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Figure 1 (A) Schematic representation of the AP-1-conjugated liposome. Liposomes were prepared containing maleimide functional polyethylene glycol chains. Maleimide 
was used to attach the AP-1 peptide through the thiol group on a cysteine. (B) Flow cytometric detection of the cell-surface interleukin-4 receptor on cloned human 
GBM8401-luc cells. (C) Linearity of measured bioluminescence versus GBM8401-luc cell number. GBM8401-luc cells were plated into 96-well dishes in triplicate in various 
numbers, and were then imaged by the in vivo imaging system. A strong correlation (R2 = 0.996) was observed between luciferase activity and cell numbers. (D) A luciferase 
image of the plated GBM8401-luc cells.
Abbreviations: IL-4R, interleukin-4 receptor; Lipo-Dox, liposomal doxorubicin.
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Systems, Minneapolis, MN) and DyLight488 fluorescent-
labeled rabbit antimouse antibody (Rockland Immuno-
chemicals, Gilbertsville, PA). The expression level of the 
interleukin-4 receptor chain was analyzed by FACSCalibur 
(Becton Dickinson, San Jose, CA, Figure 1B).
Enzyme-linked immunosorbent assay
Proteins for enzyme-linked immunosorbent assay (ELISA) 
analysis were isolated from fresh tissue using T-Per extrac-
tion reagent (Pierce Biotechnology Inc, Rockford, IL) accord-
ing to the manufacturer’s recommendations, with the addition 
of the Halt protease inhibitor cocktail (Pierce Biotechnology 
Inc). Protein concentrations were determined using the Pierce 
660 nm protein assay reagent (Pierce Biotechnology Inc). 
Protein levels in the tissue supernatant were measured by 
ELISA using either a mVEGF Quantikine (R&D Systems) kit 
or an ELISA kit for the human interleukin-4 receptor (Uscn 
Life Science Inc), following the manufacturer’s instructions. 
The results were corrected for total protein concentration and 
are reported as picograms of vascular endothelial growth 
factor/interleukin-4 receptor per microgram of protein.
Pulsed HIFU system and treatment
The pulsed HIFU sonications were generated by a 1.0 mHz 
single-element focused transducer (A392S, Panametrics, 
Waltham, MA). The focal zone of the therapeutic transducer 
was in the shape of an elongated ellipsoid, with a radial 
diameter (-6dB) of 3 mm and an axial length (-6dB) of 
26 mm. The ultrasound-driving system and equipment setup 
were the same as used in our previous studies.22 Ultrasound 
contrast agent (SonoVue, Bracco International, Amsterdam, 
Netherlands) was injected into the tail vein of the mice 
about 10 seconds before each sonication. The agent contains 
phospholipid-coated microbubbles at a concentration of 1 to 
5 × 108 bubbles/mL, with the bubbles having a mean diameter 
of 2.5 µm. The ultrasound beam was delivered to one location 
in the left brain hemisphere centered on the tumor injection 
site. The following sonication parameters were used: an 
acoustic power of 2.86 W (corresponding to peak-negative 
pressure of 0.7 MPa) with an injection of 300 µL/kg ultra-
sound contrast agent; a pulse repetition frequency of 1 Hz; 
and a duty cycle of 5%. Each sonication time was 60 seconds. 
In order to increase drug accumulation in the tumor region 
effectively, all mice were sonicated a second time 20   minutes 
after the first sonication and injected intravenously with 
ultrasound contrast agent before each sonication.
Five days after tumor cell implantation, the glioma-
bearing mice were divided into two groups. One group (n = 8) 
received liposomal doxorubicin followed by repeated pulsed 
HIFU. Another group (n = 8) were treated with AP-1 lipo-
somal doxorubicin followed by repeated pulsed HIFU. The 
concentration of liposomes that was administered to the mice 
via tail vein injection corresponded to 5 mg/kg. A control 
group of six mice were injected with GBM8401 glioma cells 
but received no treatment.
Quantitative measurement  
of doxorubicin
Animals were put into a state of deep anesthesia with an 
overdose of pentobarbital. The brain was perfused by the 
transcardiac method with normal saline for 3.5 hours after 
doxorubicin administration in order to flush out unabsorbed 
doxorubicin from the cerebral vessels. The site of tumor 
tissue was harvested along with its contralateral counterpart 
as a   control. Doxorubicin was extracted from the tumor 
and control tissues by homogenization and refrigeration for 
24 hours in 20 volumes of acidified ethanol at 4°C. Tissues 
were centrifuged at 16,000 g for 25 minutes at 4°C and the 
supernatant stored at -20°C until the fluorometric assay.23 The 
concentration of doxorubicin present was measured using a 
spectrophotometer (PowerWave 340, BioTek, Winooski, VT; 
excitation 480 nm and emission 590 nm) and the value was 
determined by taking the average of at least three fluorometric 
readings. The doxorubicin present in the tissue samples was 
quantified using a linear regression standard curve derived 
from seven concentrations of doxorubicin; the amount of 
doxorubicin is denoted in absorbance per gram of tissue.
Bioluminescence imaging
To assess the cultured GBM8401-luc cells, we imaged the 
luciferase signal by adding phosphate buffer solution or col-
orless Opti-MEM® medium (Invitrogen) with luciferin at a 
concentration of 0.15 mg/mL. Cells were imaged 10   minutes 
after luciferin administration (Figure 1C and D). Tumor 
Table 1 Composition and properties of prepared liposomal doxorubicin and AP-1 liposomal doxorubicin
Formulation Composition (molar ratio) Particle size (nm) Zeta potential (mV) Dox concentration (mg/mL)
Lipo-Dox 6:4:0.5 101.0 ± 24.5 -23.9 ± 4.8 1.87
AP-1 Lipo-Dox 6:4:0.5:0.15 116.1 ± 30.3 -26.6 ± 3.7 1.66
Abbreviation: Lipo-Dox, liposomal doxorubicin.
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size was quantified by analysis of their biophotonic images 
obtained from 5 days to 16 days after tumor implantation. 
The mice received injections of 4.29 mg per mouse of freshly 
prepared luciferin substrate suspended in phosphate buffer 
solution. After induction of anesthesia with isoflurane (1.5 L 
oxygen + 4% isoflurane per minute), the mice were imaged 
using an in vivo imaging system (Xenogen, Palo Alto, CA); 
this occurred 10 minutes after the intraperitoneal injection of 
luciferin using a one-minute acquisition time in small binning 
mode. Luciferase activity was viewed and quantified using 
Living Image software from Xenogen for a region of interest 
that encompassed the head of the mouse after anesthesia and 
administration of luciferin substrate.
Magnetic resonance imaging
MRI was performed using a 3-T MRI system (TRIO 3-T 
MRI, Siemens Magnetom, Germany). The mice were 
anesthetized with isoflurane mixed with oxygen during the 
imaging procedure. A loop coil (Loop Flex Coil, approxi-
mately 4 cm in diameter) for RF reception was used. Tumor 
progression was evaluated by means of T2-weighted images 
obtained on day 12 after tumor implantation. The imaging 
plane was located across the center of the tumor injection 
site. Parameters for T2-weighted images were as follows: 
repetition time/echo time 3500/75 msec; matrix 125 × 256; 
field of view 25 × 43 mm; and section thickness 1.0 mm.
Histological examination
After MRI scanning, the brains of the mice were prepared for 
histological assessment. Two tumor-bearing mice each from 
the repeated pulsed HIFU plus AP-1 liposomal doxorubicin 
group, from the repeated pulsed HIFU plus the liposomal 
doxorubicin treatment group, and the control group were 
sacrificed 12 days after tumor implantation for histological 
assessment. The mouse was perfused with saline and 10% 
neutral buffered formalin. Tissue sections from the mouse 
brains were fixed in paraformaldehyde and the sections 
stained with hematoxylin and eosin (Thermo-Scientific, 
Waltham, MA). Photomicrographs of the hematoxylin and 
eosin-stained tissue sections were obtained using a Mirax 
Scan digital microscope slide scanner (Carl Zeiss, Mirax 
3D Histech) with a Plan-Apochromatic 20/0.8 objective. 
The serial histology images were annotated using Panoramic 
Viewer software.
Statistical analysis
All values are shown as the mean ± standard error of the 
mean. Statistical analysis was performed using the unpaired 
Student t-test. Statistical significance was defined as a 
P value #0.05.
Results
Concentration of doxorubicin  
and intensity of pulsed HIFU
Figure 2A shows the growth of tumor cells in the control mice 
with no treatment (n = 3). Compared with cell numbers on day 
5 after implantation, there was a significant increase in tumor 
cell numbers on days 12, 16, and 20. The number of tumor 
cells showed a significant decrease when the mice received a 
single dose of liposomal doxorubicin at 10 mg/kg compared 
with a dose of 5 mg/kg. In addition, there was no significant 
difference in the bodyweight change after treatment with these 
two doses of drug (Figure 2B). In the normal brains, pulsed 
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Figure  2  Influence  of  the  concentration  of  liposomal  doxorubicin  on  tumor 
progression and bodyweight. (A) Control mice are indicated by ●. Tumor-bearing 
mice  were  treated  on  day  5  with  different  doses  of  liposomal  doxorubicin 
(▼,  5  mg/kg;  ○,  10  mg/kg).  Each  point  consisted  of  three  mice.  *Significant 
difference in control mice over the three days following cell numbers on day 5 after 
implantation. There was a significant difference between the tumors treated with 
liposomal doxorubicin at doses of 5 mg/kg or 10 mg/kg and control tumors on day 
12 after implantation. (B) Body weight change (relative to day 1) of tumor-bearing 
mice treated with different doses of liposomal doxorubicin. 
Notes: *P , 0.05; #P , 0.05; n = 3.
Abbreviation: Lipo-Dox, liposomal doxorubicin.
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HIFU exposure (2.86 W or 4.29 W) significantly increased 
the doxorubicin concentration in the brain (Figure 3A). To 
reduce the systemic toxicity of the drug and tissue damage 
induced by sonication, doxorubicin accumulation was there-
fore quantified in tumor-bearing brains after injection of 5 mg/
kg doxorubicin followed by 2.86 W of repeated sonications. 
Figure 3B indicates that interleukin-4 receptor expression 
by the tumor tissue and vascular endothelial growth factor 
expression by the   surrounding tissue did not significantly 
change after pulsed HIFU sonication of 2.86 W.
Doxorubicin deposition in brains  
and tumors
We used spectrophotometry to measure the average tumor 
doxorubicin concentration (in micrograms per gram of 
tissue) for three mice from each group. Doxorubicin was 
extracted from the tumor and contralateral control regions 
of the harvested brains treated with untargeted liposomal 
doxorubicin or AP-1 liposomal doxorubicin. Figure 4A shows 
the mean concentration of doxorubicin per unit mass for the 
brain tumors and the contralateral normal brain tissues with 
or without repeated sonication after untargeted liposomal 
doxorubicin or AP-1 liposomal doxorubicin   administration. 
Not only was the concentration of doxorubicin in the 
nonsonicated tumor significantly greater than that in the 
contralateral normal brain region, but it was also found that 
the concentration of doxorubicin significantly increased at 
the tumor site after repeated sonication compared with the 
nonsonicated tumor for the two treatments. Repeated pulsed 
HIFU exposure administered after the drugs were introduced 
increased the doxorubicin concentration in the tumor by 
441% and 374% for untargeted liposomal doxorubicin and 
AP-1 liposomal doxorubicin, respectively. Additionally, the 
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Figure 3 (A) Concentration of doxorubicin delivered to the brain as a function of 
acoustic power. Compared with the nonsonicated normal brain, there was a significant 
difference  for  sonicated  brains  at  2.86  W  or  4.29  W.  **,#/##Significant  difference 
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There was no significant difference in protein expression of the interleukin-4 receptor 
(B) or vascular endothelial growth factor (C) after pulsed HIFU exposure. 
Notes: #P , 0.05; **P , 0.01; ##P , 0.01; n = 3).
Abbreviations:  Lipo-Dox,  liposomal  doxorubicin;  HIFU,  high-intensity  focused 
ultrasound; VEGF, vascular endothelial growth factor.
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Figure 4 (A) Measurements of untargeted liposomal doxorubicin and AP-1-conjugated 
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and with repeated sonication. Compared with the contralateral normal brain, there 
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concentration of doxorubicin was significantly greater at 
the tumor site with the untargeted liposomal doxorubicin 
followed by repeated sonication than for the nonsonicated 
tumor treated with targeted liposomal doxorubicin without 
sonication (P , 0.05). Compared with the control tumor, 
there was a significant increase in the derived tumor-to-
contralateral brain ratios for the repeatedly sonicated tumor 
treated with either drug (Figure 4B). Importantly, however, 
the derived tumor-to-contralateral brain ratio was signifi-
cantly greater after repeated sonication for the untargeted 
liposomal doxorubicin group than for the targeted liposomal 
doxorubicin group without sonication.
Antitumor effect on tumors treated 
with untargeted or targeted liposomal 
doxorubicin followed by repeated 
sonication
The control tumors and the effect of tumors treated on day 5 
by untargeted liposomal doxorubicin or targeted liposomal 
doxorubicin in combination with repeated pulsed HIFU 
on tumor progression were monitored by bioluminescence 
imaging over time (Figure 5). Tumor cells spread rapidly 
in the untreated control mice (Figure 5, top). When the 
intracranial brain tumors were treated with untargeted 
liposomal doxorubicin or targeted liposomal doxorubicin, 
in both cases followed by repeated pulsed HIFU, a similar 
pattern of tumor progression was followed. Tumor treatment 
by liposomal doxorubicin or AP-1 liposomal doxorubicin 
with repeated sonication significant slowed the growth of 
the tumors by day 12 after implantation (Figure 6A). Both 
treatment protocols were associated with no statistically sig-
nificant decrease in body weight compared with the animals 
with untreated control tumors (Figure 6B).
MRI and histological evaluation
The effects of the various treatment protocols on tumor 
progression were monitored by MRI and also evaluated by 
hematoxylin and eosin staining on day 12 after implantation 
(Figure 7). Based on the MRI and histology, tumor progres-
sion was found to be consistent with the bioluminescence 
imaging (Figure 5) and no significant difference in the tumor 
size was found between the treatment groups.
Discussion
This study was designed to investigate the applicability of 
repeated pulsed HIFU exposures when treating brain tumors 
with high-dose chemotherapeutic agents. This study shows 
that repeated sonications could significantly increase the 
concentration of drugs in the brain tumor. Combining the 
repeated sonications with either untargeted liposomal doxo-
rubicin or targeted liposomal doxorubicin was found to have 
a similar and significant antitumor effect.
Several studies have indicated that poor distribution and 
limited penetration by doxorubicin into solid tumors are 
the main causes of its deficiency as a therapeutic agent.24,25 
  Long-circulating chemotherapies delivered through lipid nano-
particles have been approved to deliver drugs into brain tumors 
passively by the enhanced permeability and retention effect.26 
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Figure 5 Longitudinal bioluminescence imaging of the brain tumors was monitored from 5 to 16 days after implantation. Firefly luciferase-labeled GBM8401 cells had been 
implanted into the left forebrain of NOD-scid mice which received no treatment (control), post-treatment with repeated pulsed HIFU after liposomal doxorubicin on day 5, 
or post-treatment with repeated pulsed HIFU after AP-1 liposomal doxorubicin injection on day 5.
Abbreviations: AP-1, atherosclerotic plaque-specific peptide-1; Lipo-Dox, liposomal doxorubicin; HIFU, high-intensity focused ultrasound.
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It has been demonstrated that focused ultrasound is able to 
improve the therapeutic efficacy of liposomal doxorubicin in 
a breast cancer tumor model.27 Previous studies have demon-
strated that repeated sonication can significantly increase the 
efficiency of drug delivery when microbubbles are present for 
sonication.11,28 Our strategy is to use repeated pulsed HIFU to 
deliver and concentrate the high-dose chemotherapeutic agent 
into the brain tumor at a minimal systemic dosage (Figure 2A). 
Moreover, repeated sonications not only significantly enhance 
the concentration of doxorubicin but also significantly elevate 
the tumor-to-normal brain ratio in the sonicated tumor tissue.
In our in vitro pilot study, colocalized expression of 
tumor cells was significantly greater for treatment with AP-1 
liposomal doxorubicin than for treatment with untargeted 
liposomal doxorubicin. Figure 4 shows that repeated pulsed 
HIFU administered after AP-1 liposomal doxorubicin was 
introduced gave the highest doxorubicin concentration and 
tumor-to-normal brain ratio at the sonicated tumor. However, 
there were no significant differences between the group treated 
with AP-1 liposomal doxorubicin and a similar approach using 
untargeted liposomal doxorubicin. This is consistent with the 
similar antitumor effects seen in   Figure 6A. One possible rea-
son could be that drug delivery was limited by the blood-brain 
barrier in the in vivo study. Therefore, the targeting ability of 
AP-1 would not be obvious due to low drug concentration in 
the tumor tissue. Additionally, the concentration of doxorubicin 
was significantly greater at the tumor site with the untargeted 
liposomal doxorubicin followed by repeated sonication than 
for the nonsonicated tumor treated with targeted liposomal 
doxorubicin alone (P , 0.05). Thus, our results show that 
doxorubicin accumulation in the tumor occurring with the 
untargeted drug followed by repeated pulsed HIFU is signifi-
cantly higher than with targeted doxorubicin alone. In parallel, 
the tumor-to-normal brain ratio is also significantly elevated by 
repeated sonication compared with targeted liposomal doxo-
rubicin without sonication (Figure 4B). Therefore, liposomal 
doxorubicin delivery to the tumor by repeated sonication is 
much more efficient than that obtained using IL-4 receptor-
targeted liposomal doxorubicin without sonication.
Chemical modification of drugs and biological agents 
are methods often used to help an agent cross through the 
blood-brain barrier into a brain tumor. However, by traditional 
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Figure 6 (A) Analysis of increases in tumor size (relative to day 5) is based on 
data  obtained  from  bioluminescence  images  in  Figure  5.  Compared  with  the 
control tumor mice, * and # denote a significant difference for untargeted liposomal 
doxorubicin with repeated sonication and AP-1 liposomal doxorubicin with repeated 
sonication, respectively. (B) Bodyweight change (relative to day 5) of tumor-bearing 
mice treated by untargeted liposomal doxorubicin with repeated sonication and 
AP-1 liposomal doxorubicin with repeated sonication. 
Notes: *P , 0.05; #P , 0.05.
Abbreviations: AP-1, atherosclerotic plaque-specific peptide-1; Lipo-Dox, liposomal 
doxorubicin; HIFU, high-intensity focused ultrasound.
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Figure 7 Twelve days after tumor implantation, three mice each from the control 
group, the untargeted liposomal doxorubicin with repeated sonication group, and 
the  AP-1  liposomal  doxorubicin  with  repeated  sonication  group  were  imaged  by 
T2-weighted magnetic resonance imaging (A, coronal view; B, axial view), and then 
sacrificed for hematoxylin and eosin (C) histological examination (scale bar, 2000 µm).
Abbreviations: AP-1, atherosclerotic plaque-specific peptide-1; Lipo-Dox, liposomal 
doxorubicin; HIFU, high-intensity focused ultrasound.
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means, in order that sufficient drugs can be delivered to the 
tumor tissue, the drug dose often needs to be at toxic levels. 
Pulsed HIFU is a physical assistance method that enhances 
delivery of chemotherapeutic agents to the targeted region of 
the brain. There are several mechanisms that may be involved 
in enhancing drug propagation through the blood-brain bar-
rier, such as blood-brain barrier disruption or widening of 
the intercellular gaps, both of which can increase transport 
into the tumor site. Furthermore, pulsed HIFU can shorten 
peak tumor uptake times and increase peak tumor uptake 
values compared with unsonicated tumors.29 Our previous 
study has demonstrated that the blood-brain barrier was 
transiently disrupted by pulsed HIFU.9 In the present study, 
regardless of whether untargeted or targeted drugs are used, 
focused ultrasound offers a local and efficient method for 
delivering either drug (Figure 4A). High-dose chemotherapy 
has yielded favorable results when treating brain metastases 
or primary brain tumors.30 Using pulsed HIFU to allow deliv-
ery of high-dose therapeutic agents to brain tumors using 
standard chemotherapeutic doses is an innovative approach 
to treatment.
This study demonstrates that repeated pulsed HIFU is 
able to deliver high-dose chemotherapeutic drugs to brain 
tumors and improve the antitumor effect of the drugs at mini-
mal systemic dosage. Repeated pulsed HIFU seems to be a 
good method of achieving local high-dose chemotherapy for 
malignant glioma or other brain diseases without increasing 
systemic toxicity.
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